Gertjan Bartlema, Co-founder Populus Bio and CEO of Immodulon Therapeutics. on Innovation in Biotechs

Gertjan Bartlema, Co-founder Populus Bio and CEO of Immodulon Therapeutics. on Innovation in Biotechs

In this episode, I spoke with Gertjan Bartlema, the co-founder Populus Bio and CEO of Immodulon Therapeutics. Over 20 years in big pharma at Celgene/Amgen and then moved into the fast pace world of biotech. From here, he has been challenging the status quo and asking the question “Is our current drug development approaches sustainable?”. Gertjan highlights the need for better clinical trial designs and the importance of making objective decisions based on data. He also offers valuable insights for aspiring executives on leadership and team dynamics.

Here's what you're in:

  • How many drugs fail end-points due to Bad Leadership?
  • Why does Gertjan believe sequential and traditional drug Development can kill innovation within Drug Development?.
  • What advice does Gertjan give to those wanting to become a CEO?

Timestamps:

02:53 The Abraxane Course Correction

06:03 Gertjan’s Journey into Life Sciences

10:40 Leaving Celgene and New Ventures

15:50 Bayesian Statistics in Clinical Studies

19:27 Mistakes Companies Are Still Making Today

25:38 The Ambitious People

35:46 Advice for Aspiring Executives


About Gertjan

Gertjan Bartlemais co-founder of Populus Bio and current CEO of Immodulon Therapeutics which is running cancer trials focusing on a broad spectrum immunomodulator. He is a global biotech executive with extensive experience in EU and US operational roles and he is a member of founding Celgene EMEA management establishing EU footprint and launching Revlimid. Prior to joining Immodulon, he was the Chief Business Officer of Vico Therapeutics, and spent 12 years with Celgene, where he led the trial of Revlimid. Gertjan holds MSc in Economics from Maastricht University.


Connect with Gertjan

LinkedIn: https://www.linkedin.com/in/gertjan-bartlema/

Populus Bio: https://populusbio.com/

Immodulon Therapeutics: https://www.immodulon.com/


About me

My name is Charles Spence and I lead Discera. After many years working in the life-science recruitment world, I decided to work for myself. Before doing recruitment I graduated with a biomedical degree, have worked in hospitals (including translation work in Seoul, South Korea), and also spent a year working in diabetes research in Stockholm. After doing research and travel, a career in business and science felt the most appropriate.

In 2023, I decided to launch my firm - Discera Search. A firm committed to solving the biggest talent needs of early clinical stage SME biotechs on the East Coast and DACH.


Connect with me:

LinkedIn: https://www.linkedin.com/in/charles-spence-clinical/

Website: https://www.discera-search.com/



Opinions and comments expressed by the guest do not represent the company and are fully their own.


Denne episoden er hentet fra en åpen RSS-feed og er ikke publisert av Podme. Den kan derfor inneholde annonser.

Episoder(71)

Tobias Kampfenkel, MD, MHBA, Vice President of Early Clinical Development and Translational Research at Miltenyi Biomedicine, on Transformative Drugs in Oncology and Autoimmunity: It's Always the Team!

Tobias Kampfenkel, MD, MHBA, Vice President of Early Clinical Development and Translational Research at Miltenyi Biomedicine, on Transformative Drugs in Oncology and Autoimmunity: It's Always the Team!

In this episode, I talked with Dr. Tobias Kampfenkel, Vice President of Early Clinical Development and Translational Research at Miltenyi Biomedicine. Tobias spent nearly a decade at Janssen building ...

15 Jun 39min

Sofia Heigis, CEO of OncoPeptides, From Sales Rep to CEO, Being "Present", and Hiring for Self-Insight

Sofia Heigis, CEO of OncoPeptides, From Sales Rep to CEO, Being "Present", and Hiring for Self-Insight

In this episode, I talked with Sofia Heigis, Chief Executive Officer of OncoPeptides, about a career path that did not start where she expected. Sofia originally wanted to move into clinical operation...

31 Mai 38min

Jens Lindberg, CEO at Medivir, on The Biotech Rollercoaster - Medivir´s Previous Four Months (and Biotech Today in 2026)

Jens Lindberg, CEO at Medivir, on The Biotech Rollercoaster - Medivir´s Previous Four Months (and Biotech Today in 2026)

In this episode, I talked with Jens Lindberg, CEO of Medivir AB, a Swedish biotech developing innovative therapies in liver cancer and rare disease. Jens brings over 30 years of late-stage development...

18 Mai 33min

Hubert Truebel,  Managing Director at DEBRA Research, on Creating Own Career Opportunities...and a Practical Approach to Longevity

Hubert Truebel, Managing Director at DEBRA Research, on Creating Own Career Opportunities...and a Practical Approach to Longevity

In this episode, I talked with Hubert Truebel, Managing Director at DEBRA Research, to discover a career that wasn’t built traditionally—but through creating opportunities where none formally existed....

4 Mai 28min

Sampreet Ramachandra, Head of Hematology Business Unit at Novartis Germany, on Launching Without a Playbook, Hiring Mistakes, and Leading with Equity

Sampreet Ramachandra, Head of Hematology Business Unit at Novartis Germany, on Launching Without a Playbook, Hiring Mistakes, and Leading with Equity

In this episode, I talked with Sampreet Ramachandra, Head of the Hematology Business Unit at Novartis Germany, about what it really takes to lead high-stakes launches — and what leadership looks like ...

30 Mar 42min

Volker Wacheck, SVP at Taiho Oncology in Speaking Up, Asking vs. Accusing and Why Culture is So Important

Volker Wacheck, SVP at Taiho Oncology in Speaking Up, Asking vs. Accusing and Why Culture is So Important

In this episode, I talked with Volker Wacheck, SVP & Head of Clinical Development at Taiho Oncology, where he shared how a PI role in Vienna led him into industry, and why the hardest part wasn’t leav...

9 Mar 29min

Dena Grayson, MD, PhD, SVP Clinical Development & Medical Affairs at Kyverna Therapeutics on Media Training, Communication within Biotech, and Dealing with Fake CVs

Dena Grayson, MD, PhD, SVP Clinical Development & Medical Affairs at Kyverna Therapeutics on Media Training, Communication within Biotech, and Dealing with Fake CVs

In this episode, I talked with Dr. Dena Grayson, a physician–scientist with over two decades in biotech drug development. At the time of this recording, she was SVP and Head of Clinical Development at...

24 Feb 31min

Richard Nkulikiyinka, Chief Medical Officer at Antag Therapeutics, on Career Pivots, Trust and Why Leadership Is Never Linear

Richard Nkulikiyinka, Chief Medical Officer at Antag Therapeutics, on Career Pivots, Trust and Why Leadership Is Never Linear

In this episode, I talked with Richard Nkulikiyinka, Chief Medical Officer at Antag Therapeutics, a Copenhagen-based biotech developing GIPR antagonists in the obesity space.Richard’s career began in ...

26 Jan 35min

Populært innen Business og økonomi

stopp-verden
lydartikler-fra-aftenposten
dine-penger-pengeradet
rss-penger-polser-og-politikk
e24-podden
rss-borsmorgen-okonominyhetene
rss-skravla-gar
pengepodden-2
rss-pa-konto
finansredaksjonen
tid-er-penger-en-podcast-med-peter-warren
utbytte
livet-pa-veien-med-jan-erik-larssen
morgenkaffen-med-finansavisen
okonomiamatorene
lederpodden
liberal-halvtime
rss-kron-podden
paretopodden
rss-impressions-2